Compare Abeona Therapeutics Inc (ABEO) vs iShares Core US Aggregate Bond ETF (AGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Core US Aggregate Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.57 (market cap $424.33M), while iShares Core US Aggregate Bond ETF trades at $97.72. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | AGG | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Fixed Income |
52-Week High | $7.45 | $101.40 |
52-Week Low | $4.17 | $97.24 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
AGG trades at $97.6, up 0.17% on the day, with a neutral technical signal and bearish moving averages. Recent news highlights institutional accumulation and bond ETF inflows amid fluctuating Treasury yields. The ETF offers consistent dividends, with the latest payments scheduled for 2026.
Outlook remains tied to interest rate trends and inflation data, presenting income stability but facing pressure from rising yields. Key risks include Fed policy shifts and geopolitical impacts on oil prices, while institutional buying signals confidence in fixed-income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →
